BIOMAT Database Logo BIOMAT Database Logo

[Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans]. 1985

E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D010984 Platinum A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae". Platinum Black
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
January 1983, Cancer chemotherapy and pharmacology,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
January 1982, Cancer chemotherapy and pharmacology,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
April 1984, Cancer research,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro.
August 1987, Cancer research,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
January 1984, Cancer chemotherapy and pharmacology,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia.
November 1989, Cancer research,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
January 1984, Investigational new drugs,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
[Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
April 1989, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
August 1991, The Journal of toxicological sciences,
E Zucca, and M T Cattaneo, and F Cavalli, and A Guaitani, and V Filipazzi, and I Bartosek
Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
January 1992, Anticancer research,
Copied contents to your clipboard!